Compare ARI & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARI | AGIO |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2009 | 2013 |
| Metric | ARI | AGIO |
|---|---|---|
| Price | $10.17 | $27.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $10.83 | ★ $36.25 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 02-09-2026 | 02-12-2026 |
| Dividend Yield | ★ 9.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $269,296,000.00 | $44,791,000.00 |
| Revenue This Year | $23.46 | $27.83 |
| Revenue Next Year | $16.03 | $134.79 |
| P/E Ratio | $11.38 | ★ N/A |
| Revenue Growth | ★ 67.16 | 36.26 |
| 52 Week Low | $7.70 | $22.24 |
| 52 Week High | $11.11 | $46.00 |
| Indicator | ARI | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 45.23 |
| Support Level | $9.81 | $27.30 |
| Resistance Level | $10.02 | $28.87 |
| Average True Range (ATR) | 0.19 | 1.00 |
| MACD | 0.03 | 0.30 |
| Stochastic Oscillator | 95.61 | 26.55 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.